Science Daily1h
Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
Pfizer succeeds in late-stage trial for colorectal cancer therapy
Pfizer (NYSE:PFE) announced Saturday that its colorectal cancer therapy Braftovi, as part of a combination regimen, reduced tumor size (confirmed objective response rate) in a late-stage trial with a ...
emjreviews.com6h
Novel Urine Test Detects Early-Stage Bladder Cancer with 90% Accuracy
EARLY-STAGE bladder cancer can be effectively diagnosed using unprocessed urine samples at the point of care, achieving 90% ...